Company dynamics
- On 27 April 2026, Shengda Bio-Pharm released its 2025 annual report and 2026 first‑quarter report.
- On 21 April, 2026, Kingdomway released its 2025 annual report and special report on raised fund deposition and utilization.
- On 8 April, 2026, Zhenhua Chemical disclosed the listing sponsorship letter issued by Huatai United Securities for its convertible bonds.
- On 2 April, 2026, Hubei Nengter Technology issued an announcement regarding receipt of the Notice of Case Filing from the CSRC.
Project progress
- On 20 April, 2026, Shandong Sauhoe proposes 70 t/a VK3 pilot-scale project.
- On 17 April, 2026, Brother Pharma plans vitamin and catalytic material technical transformation project.
- On 17 April, 2026, Kangerhui Pharma advances 2,000 t/a phenyl ether ketone and bromides, and 1,500 t/a acetamidine hydrochloride project.
- On 9 April, 2026, Synsea Biopha's 10,000 t/a bio-based vitamins and oils project was filed.
The USD/RMB exchange rate in this Report is USD1.00=CNY6.9025 on 1 April, 2026, sourced from the People's Bank of China. All the prices mentioned in this Report will include the VAT, unless otherwise specified.

